Terns Pharmaceuticals stock stops trading as Merck’s $53 cash deal takes over the chart

Terns Pharmaceuticals shares aren’t budging—not surprising, since the merger is done and Nasdaq trading is finished. The last quote for the stock came in at $52.95, just shy of Merck’s $53-per-share cash deal. With Terns now fully absorbed into Merck, its common stock has dropped off the Nasdaq Global Select Market and won’t trade again.